Skip to main content

Full text of "USPTO Patents Application 09804625"

See other formats


USSNTBD 
September 9, 1997 
Page 2 

AMENDMENT 

IN THE CLAIMS: 

Please add new claims 24 - 85 as follows: 



^ -24. An isolated DNA molecule comprising a DNA sequence selected from the group consisting 

(a) nucleotides 1202 through 1543 of Figure 2; 

(b) nucleotide 1252 through 1543 of Figure 2;' 

(c) nucleotides 1279 through 1626 of Figure 3; 

(d) nucleotides 1333 through 1626 of Figure 3; 

(e) nucleotides encoding amino acids 283 through 396 of Figure 2; 

(f) nucleotides encoding amino acids 299 through 396 of Figure 

(g) nucleotides encoding amino acids 293 through 408 of Figure 3* 

(h) nucleotides encoding amino acids 311 through 408 of Figure 3- and 

of (a) through (h). ( ° natUraUy ° CCUrTing ^ SCqUenCeS ^ equivalent de S ene ™^ codon sequences 
of Figure^'. ^ ^ C0m P risin - 2 a DNA of nucleotides 1 202 through 1 543 

of Figured. ^ ° NA m ° leCU,e com P risin § a DNA se <^nce of nucleotide 1252 through 1543 

of Figure 2 ! ^ com P risin S a DNA of nucleotides 1279 through 1626 

ofFigure 2 3. An isolated DNA molecule comprising a DNA sequence of nucleotides 1333 through 1626 

283 through 396 Fi^el^ * DNA ° f nUde ° tides encodin § ™™ ^ 

299 through 396 rf^f 2 DNA * SeqU6nCe of nucleotides amino adds 

293 through 408^ Rg^"* * DNA ° f nUde ° tideS encodin * ™™ 

3 1 1 through 408 rfR^T3 DNA * ° NA ° f nUC,eotides amino acids 

of « -od.*"^^^ ^ —s to a DNA sequence 

of c.« undet^^ BMP-4 protem which hybridizes to a DNA sequence 

control sequence tefor COmPriSinS * ^ ° f ^ 24 fa 0peratiVe aSSOciadon » «P*«ion 



control uence A d^ C ° mPriSing " ° f ^ 33 in °^ VS with an expression 

control sf q uence A tofor COmPriSing " ° NA ° f ^ 34 in association Wlth » expression 



USSNTBD 
September 9, 1997 
Page 3 

38. A host cell transformed with a vector of claim 35. 

39. A host cell transformed with a vector of claim 36. 

40. A host cell transformed with a vector of claim 37. 

41 . An isolated DNA molecule comprising a DNA selected from the group consisting of ATCC 
deposits 40345 and 40342. 

42. A method for producing a BMP-2 protein said method comprising the steps of: 

(a) culturing a host cell transformed with a DNA sequence of claim 33, and; 

(b) recovering said BMP-2 protein. 

43. A method for producing BMP-4 protein, said method comprising the steps of: 

(a) culturing a host cell transformed with a DNA sequence of claim 34, and; 

(b) recovering said BMP-4 protein. 

44. A BMP-2 made by the method of claim 42. 
(45/) A BMP-4 made by the method of claim 43. 

45T A purified BMP-2 polypeptide comprising an amino acid sequence encoded by a DNA 
sequence comprising nucleotides 1202 through 1543 of Figure 2. 

47. A purified BMP-2 polypeptide comprising an amino acid sequence encoded by a DNA 
sequencecomprising nucleotides 1252 through 1543 of Figure 2. 

^87) A purified BMP-4 polypeptide comprising an amino acid sequence encoded by a DNA 
sequencecomprising nucleotides 1279 through 1626 of Figure 3. 

(4ST) A purified BMP-4 protein comprising an amino acid sequence encoded by a DNA sequence 
comprising nucleotides 1333 through 1626 of Figure 3. 



50. 
of Figure 2. 
51. 



A purified BMP-2 protein comprising an amino acid sequence of amino acid 283 through 396 

51. A purified BMP-2 protein comprising an amino acid sequence of amino acid 299 throush 396 
of Figure^ ^ 

, A Purified BMP-4 protein comprising an amino acid sequence of amino acids 293 through 

408 of Figure 3. = 

,no c A P urified BM P-4 protein encoded by an amino acid sequence of amino acids 3 1 1 through 

408 of Figure 3. 9 . 

5^ A purified BMP-2 protein encoded by a DNA sequence of claim 33. 
\g/ A purified BMP-4 protein encoded by a DNA sequence of claim 34. 
^ _^56. A pharmaceutical composition comprising a therapeutic amount of a BMP-2 polypeptide of 

A pharmaceutical composition comprising a therapeutic amount of a BMP-4 polypeptide of 

58. An antibody to a purified BMP-2 polypeptide of claim 54. 

59. An antibody to a purified BMP-4 polypeptide of claim 55. 

DUD ^ 60 r , . A method for modulating cell development comprising administering an effective amount of 
a BMP-2 of claim 54. 

in vivo 61 ^ meth0d ° f ° laim 60 ' wherein said method comprises administering BMP-2 to a patient 
BMP-4 of claim 55 mCth0d ^ m0duladng CeiI deve,0 P ment comprising administering an effective amount of 
63. The method of claim 60, wherein said method comprises administering BMP-4 to a patient 



in vivo. 



USSNTBD 
September 9, 1997 
Page 4 



64. A method for inducing cell formation, growth, differentiation, proliferation, and maintenance 
comprising administering an effective amount of a BiMP-2 protein of claim 54. 

65. A method for inducing formation of chondrocyte and/or cartilage tissue comprising 
administering a composition comprising a BMP-2 protein of claim 54. 

66. The method of claim 65, wherein said method comprises administering the composition to 
cells in vitro and recovering chondrocytes and/or cartilage tissue. 

67. A method for inducing cell formation, growth, differentiation, proliferation, and maintenance 
comprising administering an effective amount of a BMP-4 protein of claim 55. 

68. A method for inducing formation of chondrocyte and/or cartilage tissue comprising 
administering a composition comprising a BMP-4 protein of claim 55. 

69. The method of claim 68, wherein said method comprises administering the composition to 
cells in vitro and recovering chondrocytes and/or cartilage tissue. 

70. The protein of claim 54 wherein said protein is a disulfide linked dimer wherein at least one 
of the subunits of said dimer comprises BMP-2. 

\Ty The protein of claim 55 wherein said protein is a disulfide linked dimer wherein at least one 
of the suBunits of said dimer comprises BMP-4. 

72. A pharmaceutical composition comprising an effective amount of a BMP-2 protein of claim 

54 in admyo^re with a pharmaceutically acceptable vehicle. 

(73^/ A pharmaceutical composition comprising an effective amount of a BMP-4 protein of claim 

55 in admixture with a pharmaceutically acceptable vehicle. 

74. A composition for cartilage formation comprising an effective amount of a BMP-2 protein 
of clairn5£in a pharmaceutically acceptable vehicle. 

J A composition for bone and/or cartilage formation comprising an effective amount of a BMP- 
: claim 55 in a pharmaceutically acceptable vehicle. 

A composition of claim 74 further comprising a matrix for supporting said composition and 
providing^Hurface for cartilage growth. 

[ThJ A composition of claim 75 further comprising a matrix for supporting said composition and 
providing a surface for bone and/or cartilage growth. 

78. The composition of claim 76 wherein said matrix comprises a material selected from the group 
consistin^hydroxyapatite, collagen, polylactic acid and tricalcium phosphate. 

V^y The composition of claim 77 wherein said matrix comprises a material selected from the group 
consistiftg-of hydroxyapatite, collagen, polylactic acid and tricalcium phosphate. 

80. A method for inducing cartilage formation in a patient in need of same comprising 
administering to said patient an effective amount of the composition of claim 72. 

81. A method for inducing bone and/or cartilage formation in a patient in need of same comprising 
administering to said patient an effective amount of the composition of claim 73. 

82. A pharmaceutical composition for wound healing and tissue repair said composition 
compnsyg an effective amount of a BMP-2 protein of claim 54 in a pharmaceutically acceptable vehicle. 

(J83\ A pharmaceutical composition for wound healing and tissue repair said composition 
comprising' an effective amount of a BMP-4 protein of claim 55 in a pharmaceutically acceptable vehicle. 

84. A method for treating wounds and/or tissue repair in a patient in need of same comprising 
administering to said patient an effective amount of the composition of claim 82. 

85. A method for treating wounds and/or tissue repair in a patient in need of same comprising 
administering to said patient an effective amount of the composition of claim 83.-